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Background: Nephronophthisis (NPHP) is an autosomal reces-
sive cystic kidney disease that constitutes the most common
genetic cause of renal failure in the first three decades of life.
Using positional cloning, six genes (NPHP1-6) have been
identified as mutated in NPHP. In Joubert syndrome (JBTS),
NPHP may be associated with cerebellar vermis aplasia/
hypoplasia, retinal degeneration and mental retardation. In
Senior–Løken syndrome (SLSN), NPHP is associated with retinal
degeneration. Recently, mutations in NPHP6/CEP290 were
identified as a new cause of JBTS.
Methods: Mutational analysis was performed on a worldwide
cohort of 75 families with SLSN, 99 families with JBTS and 21
families with isolated nephronophthisis.
Results: Six novel and six known truncating mutations, one
known missense mutation and one novel 3 bp pair in-frame
deletion were identified in a total of seven families with JBTS,
two families with SLSN and one family with isolated NPHP.
N
ephronophthisis (NPHP) is an autosomal recessive cystic
kidney disease, which is the most common genetic cause
of end-stage renal disease (ESRD) in the first three
decades of life.1 Using positional cloning, six genes (NPHP 1–6)
have been identified to date,2–8 causing disease variants NPHP
types 1–6, respectively. NPHP can occur with isolated kidney
involvement or in combination with diverse extrarenal mani-
festations. Specifically, it can be associated with cerebellar
vermis dysplasia/hypoplasia, retinal degeneration and mental
retardation in Joubert syndrome (JBTS).8–10 NPHP may also be
associated with retinal degeneration in Senior–Løken syndrome
(SLSN) in about 10% of patients with mutations in NPHP1, 2, 3
or 44 5 11 12 and in .90% of patients with mutations in NPHP5 or
6.7 8
JBTS is an autosomal-recessive developmental disorder with
multiple organ involvement characterised by a typical neuro-
radiological feature, the ‘‘molar tooth sign’’ (MTS), which
describes a cerebellar and brainstem malformation. This entails
dysplasia or hypoplasia with or without dysplasia of the
cerebellar vermis, thick and misoriented superior cerebellar
peduncles and an abnormally deep interpeduncular fossa.10 13
Accompanying neurological symptoms of JBTS include neona-
tal hypotonia, transient abnormal breathing patterns in the
neonatal period (apnoea and/or hyperpnoea), ataxia, nystag-
mus, mental/psychomotor retardation and/or oculomotor
apraxia.10 14 15 Seizures and behavioural problems within the
autism spectrum have been described.10 JBTS and JBTS-related
disorders (JSRD), as defined by the presence of MTS with
multiorgan involvement, are clinically heterogeneous.13 Two
forms of JBTS have been determined: types A and B, the latter
being characterised by the co-occurrence of ocular and renal
features, namely retinal dystrophy and nephronophthisis.14 At
least eight distinct syndromes that have MTS as a feature have
been reported, showing wide phenotypic variability both within
and between families.13 One example is COACH syndrome15 in
which cerebellar vermis hypoplasia occurs along with oligo-
phrenia, congenital ataxia, ocular coloboma and hepatic
fibrosis. Additional extrarenal organ manifestations may
include retinal coloboma, congenital amaurosis, hepatic fibrosis
and postaxial polydactyly. MTS has also been described in
association with complex midbrain–hindbrain malformations
including Dandy–Walker malformation15 and occipital ence-
phalocoele.10 13
JBTS is genetically heterogeneous. Four genes have been
identified and two additional loci mapped for JBTS,16 including
the JBTS1 locus at chromosome 9q34.3 (OMIM 213300)17 and
the JBTS2 or CORS2 locus at chromosome 11p12-11q13.3
(OMIM 608091).18 The gene defects identified in patients with
JBTS include: (1) deletions in NPHP1 (JBTS4; OMIM 607100);10
(2) mutations in the AHI1 (Abelson helper integration site) gene
(JBTS3; OMIM 608894),10 19–21 and (3) mutations in the MKS3/
TMEM67 (Meckel syndrome type 3) gene (JBTS6) which was
initially found in patients with Meckel–Gruber syndrome
(OMIM 607361).22 In addition, using positional cloning, we
recently identified mutations in a novel gene NPHP6/CEP290
(OMIM 610142), as causing JBTS5,8 describing eight different
mutations in seven families with JBTS.8 Mutations in the same
gene were identified in five families with pleiotropic forms of
JBTS by Valente et al9 and as a major cause of JBTS with
oculorenal involvement by Brancati et al.23 Recently, a hetero-
zygous truncating mutation in NPHP6/CEP290 and a heterozygous
missense mutation in AHI1 have been found in combination with
the homozygous NPHP1 deletion in patients with NPHP and
JBTS-related neurological symptoms.24
The most common extrarenal manifestation of nephro-
nophthisis is retinal involvement. In SLSN there is the
association of NPHP with retinitis pigmentosa, tapetoretinal
degeneration or retinal dysplasia.1 About 10% of patients with
mutations in NPHP11 or NPHP46 present with SLSN. In one
patient with SLSN, a mutation in NPHP2 was identified.12 In
NPHP3, only single heterozygous mutations were found in four
patients with SLSN.4 Whether a mutation in an unknown
modifier gene is causative for the retinal involvement is
unknown.1 In NPHP5, all patients described to date have had
early-onset SLSN.7 Recently we reported a homozygous 5 bp
deletion in NPHP6/CEP290 that altered an obligatory splice site
in a patient with SLSN.8
Another condition that can occur concomitant with NPHP is
Leber congenital amaurosis (LCA; OMIM 204000) a severe
Abbreviations: ESRD, end-stage renal disease; JBTS, Joubert syndrome;
JSRD, Joubert syndrome-related disorders; LCA, Leber congenital
amaurosis; MTS, molartooth sign; NPHP, nephronophthisis; OMIM, Online
Mendelian Inheritance in Man; SLSN, Senior–Løken syndrome
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retinal dystrophy causing blindness or severe visual impairment
at birth or within the first 2 years of life. Mutations in nine
genes (AIPL1, CRB1, CRX, GUCY2D, IMPDH1, RDH12, RPE65,
RPGRIP1 and NPHP6/CEP290) have been found to cause
LCA.25 26 A hypomorphic mutation of NPHP6/CEP290 in humans
represents the most common cause of LCA.25 26 This intronic
NPHP6/CEP290 mutation (c.2991+1655ARG) accounts for 21%
of LCA cases. It creates a strong abnormal splice-donor site
leading to an insertion of a cryptic exon in intron 27 of the
CEP290 messenger RNA.25 Similarly, an in-frame deletion in the
orthologue of the gene NPHP6/CEP290 identified in the mouse
mutant rd16 causes retinal degeneration without renal or
cerebellar involvement.27 The high frequency of NPHP6/CEP290
mutations in patients with LCA was confirmed by Perrault
et al.26
Thus, mutations in NPHP6/CEP290 have been found in
disorders with cerebello-renal, cerebello-oculo-renal, cere-
bello-retinal, retinal-renal and retinal phenotypes.9 11 23 25 28 To
date, mutations in NPHP6/CEP290 had not been identified in
patients with isolated nephronophthisis. In this study we
performed mutation analysis in a worldwide cohort of 195
families with NPHP, SLSN or JBTS. We examined all translated
exons and adjacent intronic sequence and intron 27 for
mutations in NPHP6/CEP290. We found seven novel mutations
(six of them being truncating mutations), in four families with
JBTS, two families with SLSN and one family with isolated
nephronophthisis.
METHODS
Patients
We performed mutational analysis in a worldwide cohort of 195
families with JBTS, SLSN or isolated NPHP. Our cohort
comprised 99 families with JBTS (5 with diagnosis of LCA),
75 families with SLSN (6 with LCA and NPHP) and 21 families
with isolated NPHP.
We collected blood samples, pedigrees, clinical information
and informed consent (www.renalgenes.org). Approval for
studies on human subjects was obtained from the University
of Michigan institutional review board.
In all patients the diagnosis of NPHP was based on one or
more of the following criteria: (1) clinical course with
characteristic clinical signs of polyuria, polydipsia, anaemia
and growth retardation; (2) presence of chronic renal failure;
(3) renal ultrasound or renal biopsy compatible with the
diagnosis of NPHP as judged by a (paediatric) nephrologist; and
(4) pedigree compatible with autosomal recessive inheritance.
Neurological criteria for JBTS were based on the following
clinical hallmarks of this cerebello-oculo-renal syndrome: (1)
MTS or (2) diagnosis of JBTS by a (paediatric) neurologist or
geneticist. Associated JBTS symptoms were recorded: optic
nerve or retinal coloboma, tapetoretinal degeneration, cerebel-
lar vermis aplasia/hypoplasia, ataxia and periodic apnoea/
tachypnoea. The diagnosis of SLSN was based on the presence
of NPHP in association with tapetoretinal degeneration.
Analysis of NPHP1-5, AHI1 before analysis for NPHP6/
CEP290
Genomic DNA from peripheral blood samples was extracted by
standard methods. Before mutation analysis for NPHP6/CEP290
described in this study, the homozygous NPHP1 deletion and
mutations in NPHP5, both known to cause SLSN and LCA, were
excluded in patients with eye involvement. All patients with
JBTS were tested for the homozygous NPHP1 deletion and for
mutations in AHI1. All patients with isolated NPHP were tested
for the homozygous NPHP1 deletion.29 To exclude mutations in
other known NPHP genes prior to this study, 40 patients with
infantile NPHP were tested for mutations in NPHP2,29 50
patients were tested for mutations in NPHP34 29 and 95 patients
of the cohort were screened for NPHP4 mutations.28 29
NPHP6/CEP290 mutation analysis
In total, 195 samples underwent NPHP6/CEP290 mutation
analysis. Intron 27 and all 54 translated exons of NPHP6/
CEP290 were amplified by PCR using 51 exonic flanking
primers. Initially, all amplicons were prescreened by hetero-
duplex formation and a subsequent CEL I endonuclease digest
as described previously.29 The CEL I enzyme recognises single-
base mismatches present in heteroduplex DNA and cleaves
both strands. Mutations can be detected with a sensitivity of
92%.29 30 Samples showing aberrant bands in agarose-gel
electrophoresis were purified and directly sequenced. For each
mutation, 94 healthy control individuals were examined by
restriction-enzyme digest or CEL I endonuclease assay.
RESULTS
We analysed a cohort of 99 families with JBTS, 75 families with
SLSN and 21 families with isolated NPHP for mutations in
NPHP6/CEP290. Using heteroduplex analysis with CEL I
endonuclease for all 54 coding exons of NPHP6/CEP290, we
found 59 aberrant banding patterns. Direct sequencing of these
mismatches revealed 15 different nucleotide changes in 7
families with JBTS, 2 families with SLSN and 1 family with
isolated NPHP (tables 1 and 2, fig 1). These consisted of: (1)
five nonsense mutations (C3811T, C4882T, G5941T, T2249G
and C5932T) resulting in premature protein truncation
(R1271X, Q1628X, E1981X, L750X and R1978X); (2) four
deletions (5734delT, 5163delT, 1419-1423delAATAA and 164-
167delCTCA) generating frameshifts and premature stop
codons (W1912fsX1923, T1721fsX1723, K473fsX478 and
T55fsX57); (3) one start codon mutation (A1G); and (4) two
obligatory splice-site mutations (1066-1GRA, 3104-2ARG)
(table 1). Seven of these sequence variations are novel, whereas
C3811T (R1271X)23 and 5734delT (W1912fsX1923)23 in A372,
C4882T (Q1628X)23 26 and G5941T (E1981X)23 in A989,
5163delT (T1721fsX1723)23 26 in F101, T2249G (L750X)25 in
F122, and A1991G (D664G)23 have already been described. We
did not detect the intron 27 mutation25 in our cohort.
In four families (A372, A989, F101 and F57) both mutations
were found in NPHP6/CEP290, thereby indicating the phenotype
to be autosomal recessive (table 1). In four patients (F122,
A1332, F938 and F848), only single heterozygous loss-of-
function mutations could be found (table 1). Individual F848 is
known to harbour a heterozygous missense mutation in NPHP4
(C1880T, T627M).28 When parental DNA was available,
segregation analysis was performed and confirmed that the
sequence variants were transmitted as autosomal recessive
alleles. All the detected sequence variants were absent from 188
control chromosomes of people of Central European, Middle
Eastern, East Asian and American origin.
We also identified several sequence variants of unknown
significance, present in the heterozygous state: one known
missense mutation (A1991G)23 and a 3 bp in-frame deletion
(7311–7313delGAA) (fig 1, table 2). The first sequence change
results in a non-conservative amino acid substitution (D664G)
and the conserved residue of the protein (K2437 is conserved in
Ciona intestinalis). However, as this family (A854) was con-
sanguineous, the significance of this change is unknown.
Eight compound heterozygous loss-of-function NPHP6/
CEP290 mutations in four families with JBTS or SLSN
The members of the three families with JBTS (A372, A989 and
F101) and one family with SLSN (F57) in whom eight
compound heterozygous loss-of-function mutations were
found (table 1) exhibited the following disease phenotypes.
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(1) Two siblings (II-1) and (II-2) from family A372 were
diagnosed with JBTS, LCA and retinal colobomas.
(2) In patient II-1 from family A989, ESRD secondary to
NPHP occurred at 5 years of age. This patient had retinal
dystrophy type LCA, nystagmus, severe mental/psychomotor
retardation, spastic quadraparesis and liver fibrosis. The MRI
showed cerebellar vermis aplasia, supratentorial hypomyelini-
sation and hypoplastic brain stem.
(3) In patient II-2 from family F101, ESRD secondary to NPHP
was diagnosed at 9 years of age, and he was diagnosed with LCA.
Despite the fact that some of the symptoms presented by this
patient are common to JBTS (severe hypotonia in the first year of
life, mental and psychomotor retardation, sleep apnoea episodes),
the CT scan lacked the typical MTS and showed empty sella,
hypoplasia of the optic chiasm and hypothalamic hypoplasia. An
MRI was not available for review.
(4) Patient II-1 from family F57 has been visually impaired
since early childhood, lost vision progressively and was
diagnosed with retinitis pigmentosa at the age of 34 years. He
also had keratoconus. Owing to progressive renal failure
secondary to NPHP, he underwent kidney transplantation at
24 years. He had complex focal seizures at 17 years.
Figure 1 Mutations and sequence variants found in NPHP6/CEP290. (A) Eight different compound heterozygous truncating mutations in NPHP6/CEP290
were found in three families with JBTS and one family with SLSN; (B) four single heterozygous NPHP6/CEP290 mutations were found in three families with
JBTS and one family with SLSN; (C) two heterozygous sequence variants of unknown significance were found: one missense mutation in a patient with JBTS
and a 3 bp in-frame deletion in a patient with isolated NPHP (see table 2). Family number, altered nucleotide and amino acid change are given above
sequence traces and wild-type sequence below mutated sequence. One codon triplet in each chromatogram is underlined to indicate reading frame.
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Four single heterozygous NPHP6/CEP290 loss-of-
function mutations in four families with JBTS and SLSN
In three patients from families with JBTS (F122, A1332, F938)
and one patient from a family with SLSN (F848), single
heterozygous mutations were found, three of them truncating
(in F122, A1332 and F848) and one splice-site mutation (in
F938) (table 1).
Patient II-2 from family F122 had LCA and features of JBTS,
such as cerebellar vermis aplasia, muscle hypotonia at birth and
later mental/motor retardation. Symptoms and typical ultra-
sound findings of NPHP had been present since 6 years of age.
A1332 presented with dilated calyces bilaterally on ultra-
sound and normal renal function by blood testing at 18 months
of age. He had congenital amaurosis (flat electroretinogram at
15 months of age), nystagmus since birth, cerebellar vermis
aplasia and MTS, and mental and psychomotor retardation. As
his parents are consanguineous but he carries a heterozygous
mutation in NPHP6/CEP290, it is likely that there may be
recessive mutations present in other NPHP genes.
In patient II-1 from family F938, ESRD secondary to NPHP
occurred at 13 years of age. During birth, asphyxia occurred
with hypotonia. In addition, horizontal nystagmus and
esotropia were seen. In early childhood, this patient presented
with severe scoliosis and psychomotor retardation. An ophthal-
mological examination revealed retinal dystrophy.
In patient II-1 from family F848, initial symptoms of NPHP
occurred during infancy. However, ESRD occurred late, at the
age of 40 years. The patient progressively lost vision and at
44 years of age, retinitis pigmentosa (SLSN) was diagnosed. He
also had bilateral cataracts. This patient is known to harbour a
heterozygous missense mutation in the NPHP4 gene, which has
been published previously.28
Phenotypes of families with sequence variants of
unknown significance
In patient II-1 from family F459, a nonconservative missense
mutation, A1991G (D664G), was found. In a recessive disease,
this sequence variant alone cannot be disease causing. The
patient had cerebellar vermis hypoplasia, ataxia, developmental
delay and progressive hepatic fibrosis; the latter has previously
been described in COACH syndrome.15 In addition, the patient
presented with hearing loss, which has not been described
previously in association with CEP290/NPHP6 mutations
(table 2).
As oligogenic mutations of the NPHP1, AHI1 and NPHP6
genes have been described in JBTS, we examined the patients
who carried two mutations or one single heterozygous
mutation in NPHP6 for additional mutations in NPHP1 and
AHI1. However, we did not detect any additional mutations in
either gene.
NPHP6/CEP290 mutations in isolated NPHP
Interestingly, in a patient with isolated NPHP (patient II-9 from
family A854) a 3 bp in-frame deletion (7311–7313delGAA;
K2437del) was found (table 2), which was absent in 188
healthy control chromosomes. It deletes an amino acid residue
conserved in the C intestinalis orthologue of NPHP6/CEP290.
Renal symptoms (polyuria, polydipsia) and increased echo-
genicity on ultrasonography occurred at 10 years of age. To test
the possibility of NPHP6/CEP290 mutations in isolated NPHP,
we analysed 5 families that had been found to be homozygous
at the NPHP6 locus when we had performed a total genome
search for homozygosity in 105 families, and found these 5
families to be homozygous for markers in the NPHP6/CEP290
gene region. We did not find any sequence variants in these
families.
DISCUSSION
In this study, we performed mutational analysis in 195 families
with JBTS, SLSN or isolated NPHP. In total, 15 different
nucleotide changes were found, 7 of them novel. In four
patients, both compound heterozygous truncating or splice site
mutations were found. In another four patients, only single
heterozygous mutations were found; three of these mutations
were truncating and one was a splice defect (table 1). The single
heterozygous mutations are not disease-causing in themselves
in the recessive disease NPHP, but could be disease-causing in
combination with mutations in other genes.26 31
We report here one family (F848) with a heterozygous
nonsense mutation in NPHP6/CEP290 and an additional known
missense mutation in NPHP4, as published previously.28 In one
consanguineous family (A1332) only a single heterozygous
truncating mutation could be found. Tory et al reported a
patient with a homozygous deletion in NPHP1 and a hetero-
zygous truncating mutation in NPHP6/CEP290.24 These muta-
tions may potentially indicate a situation of oligogenic
inheritance as described in patients with Bardet–Biedl syn-
drome.31
In the mouse model of retinal degeneration, rd16, a 300
amino acid in-frame deletion as a hypomorphic allele was
found to be associated with early-onset retinal degeneration.27
This is consistent with the finding that the hypomorphic allele
of a partial splice defect in intron 2725 in humans leads to an
ocular phenotype only, and not to renal or cerebellar involve-
ment. Interestingly, neither kidney nor gross brain pathological
changes could be found in the rd16 mice. Mutations in NPHP6/
CEP290 have been described as the most common genetic cause
Table 2 NPHP6/CEP290 sequence variants of unknown significance
Family
(individual)
Country
of
origin
Nucleotide
alteration(s)*
Alteration(s) in
coding sequence
Exon
(segregation) PC
Age at
ESRD`
[years]
Pheno-
type
Ocular
features
(age of
diagnosis,
years)
Central nervous
system features (other)
F459 (II-2) USA A1991G, ?` D664G, ? (NC) 21 (het,Mwt) – ND JBTS ND CVA, AT, MR, RC
(hepatic fibrosis,
hearing loss)
A854 (II-9) Pakistan 7311-7313delGAA, ? K2437del (C. i.), ? 55 (het, ND) + NPHP None None
?, Second mutation not found; AT, ataxia; CVA, cerebellar vermis aplasia/hypoplasia; ESRD, end-stage renal disease; het, heterozygous in affected individual; JBTS,
diagnosed with Joubert syndrome; M, mutation identified in mother; MR, mental retardation/psychomotor retardation; Mwt maternal sequence is wild type; ND, no data
or DNA available; P, mutation identified in father; PC, parental consan-guinity; SLSN, diagnosed with Senior–Løken syndrome; RC, retinal coloboma.
*All mutations were absent from at least 188 chromosomes of healthy controls.
Evolutionary conservation: NC, non-conserved; C. i., Ciona intestinalis.
`All patients had renal ultrasonography results compatible with nephronophthisis (increased echogenicity and/or corticomedullary cysts).
`Previously published.23
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of LCA/early onset retinal degeneration.25 In our cohort there
were 11 patients with diagnosed LCA. Interestingly, mutations
in NPHP6/CEP290 were found in five of these patients. All of the
patients with JBTS with either compound or single hetero-
zygous NPHP6/CEP290 mutations identified in this study
presented with an ocular phenotype, confirming that this gene
is a major cause of JBTS with oculorenal involvement as
described previously.23
NPHP6/CEP290 mutations can be found in patients with a
spectrum of phenotypes, mainly JBTS or early-onset retinal
degeneration with additional extrarenal manifestations. We
also found NPHP6/CEP290 mutations in a patient with empty-
sella syndrome and in a patient with JBTS and an additional
manifestation of liver fibrosis. In summary, we have found six
novel loss-of-function mutations of NPHP6/CEP290.
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